Quote:The discovery that this patient’s tumor cells were CCR5-negative at baseline is a massive scientific breakthrough for CytoDyn. It provides the definitive proof that leronlimab does not need to attack the tumor cells directly to destroy the cancer. Instead, it works by completely dismantling the surrounding protective environment that shields the tumor .
Two questions. 100% of of patients in our CRC trial are CCR5 positive meaning the tumors themselves? How this problem of CCR5 occupancy (tumors vs microenvironment) may affect our ORR results for the 30% tumor reduction?
CytoDyn Inc (CYDY) Stock Research Links
Le-Ron-Li-Mab, and they have not.